What GLP-1 Therapy Actually Costs in 2026
Branded GLP-1 drugs list for well over a thousand dollars a month, yet real out-of-pocket costs run anywhere from under $100 to full price. This is a map of why the numbers vary so much — coverage, indication, savings programs, cash-pay channels, and compounding — and how to think about the cost that actually matters.
The 60-second version
What you pay for a GLP-1 depends far less on the drug than on your coverage and diagnosis. Diabetes indications are widely covered; obesity indications often are not, which is why identical-seeming drugs produce very different bills. Manufacturer copay cards help most people who already have coverage and least those who do not. Cash-pay direct programs and (a shrinking window of) compounding fill part of the gap. Because these are maintenance therapies, the figure that matters is the multi-year cost of staying on treatment, not the price of a single month.
Key takeaways
- List price (~$1,000–$1,350/month) is rarely the net price anyone pays.
- Coverage usually hinges on indication: diabetes is broadly covered, obesity often excluded.
- Copay cards help most when a plan already covers the drug; government-insured patients are typically ineligible.
- Cash-pay direct-from-manufacturer channels reshaped pricing for the uninsured.
- Compounded GLP-1s were cheaper for a structural reason, and that window has narrowed post-shortage.
- These are maintenance drugs—plan around multi-year cost, not a single fill.
The number on the label is almost never the number you pay
Sticker prices for branded GLP-1 drugs sit in the range of roughly $1,000 to $1,350 per month before any adjustment. Almost nobody pays that. Between insurance formularies, manufacturer savings programs, cash-pay direct channels, and compounded alternatives, the amount that actually leaves a person's bank account ranges from under $100 to the full list price, depending mostly on coverage and indication. Understanding the gap between list price and net price is the whole game.
Insurance: the diabetes-versus-obesity divide
The single biggest determinant of cost is whether a plan covers the drug at all, and that usually turns on indication. Coverage for type 2 diabetes (Ozempic, Mounjaro, and their peers) is broad and long-established. Coverage for obesity (Wegovy, Zepbound) is far patchier: many commercial plans exclude anti-obesity medication outright, and Medicare's statutory ban on covering drugs "for weight loss" has only narrow exceptions. The result is that two people on chemically similar drugs can face wildly different bills purely because one has a diabetes diagnosis and the other does not. When a plan does cover the obesity indication, prior authorization and step therapy are common gatekeepers.
Manufacturer savings cards and patient programs
Both major manufacturers run savings programs, and they split along the same coverage line. For commercially insured patients whose plan already covers the drug, copay cards can cut the monthly cost dramatically, sometimes to a flat low figure. For patients whose insurance excludes the drug — and for the uninsured — those same cards typically help far less, and government-insured patients (Medicare, Medicaid) are generally ineligible by rule. The programs change terms frequently, so the practical figure is the one confirmed at the pharmacy, not the one advertised.
Cash-pay direct channels
Manufacturers have increasingly sold directly to cash-paying patients, bypassing insurance entirely. These programs price single-vial or lower-dose branded product below list, which reshaped the market for people without coverage. They matter most for the group insurance serves worst: obesity patients on plans that exclude the indication. The trade-off is that the direct price is still meaningfully higher than compounded or diabetes-copay routes, and availability is tied to specific doses and formats.
Compounded GLP-1s: cheaper, and why
Through the 2022–2024 shortages, compounded semaglutide and tirzepatide filled the coverage gap at a fraction of branded cost, often a few hundred dollars a month cash. That pricing reflects a different, less-regulated supply route rather than a better deal on the same product. With the FDA shortages resolved, the legal room for routine compounding has narrowed sharply, which changes both the availability and the risk calculus. We cover that shift in depth in our companion piece on compounded GLP-1 in 2026.
The cost that matters is the multi-year cost
Monthly price is the wrong unit. These are maintenance therapies: weight regain after discontinuation is well documented, so the realistic planning horizon is years, not a single fill. A route that looks affordable this month but is not sustainable across a plan year — because a copay card expires, a prior authorization lapses, or a compounding channel closes — is a more expensive choice than a slightly higher price that holds steady. The right question is not "what does one month cost?" but "what does staying on this, or transitioning off it deliberately, cost over the time I actually intend to use it?"
Frequently asked questions
Why is Wegovy so much more expensive than Ozempic for me?
They are similar molecules, but the price difference is usually about coverage, not chemistry. Ozempic is approved for type 2 diabetes, which most plans cover; Wegovy is approved for obesity, which many plans exclude. When the obesity indication is not covered, you face a larger share of the list price.
Do the manufacturer savings cards actually work?
For commercially insured patients whose plan already covers the drug, copay cards can cut monthly cost substantially. They help far less if your insurance excludes the drug, and patients on Medicare or Medicaid are generally ineligible. Confirm the real figure at the pharmacy, since terms change often.
Is compounded GLP-1 a cheaper version of the same thing?
Not exactly. Compounded semaglutide and tirzepatide were cheaper because they came through a different, less-regulated supply route during official shortages, not because they are a discount on branded product. With the shortages resolved, the legal room for routine compounding has narrowed. See our compounded-GLP-1 article for the current picture.
Will I have to take this forever, and what does that cost?
Weight regain after stopping is well documented, so many people use these drugs long term. That makes the realistic cost a multi-year figure. A route that is affordable this month but not sustainable across years can end up costing more than a steadier, slightly higher-priced option.
Can I get GLP-1 therapy covered for weight loss on Medicare?
Historically Medicare has been barred from covering drugs used for weight loss, with only narrow exceptions such as an approved cardiovascular indication. Coverage policy in this area is actively evolving, so the specific, current answer depends on the plan and the approved use.
References
- U.S. Food and Drug Administration. GLP-1 receptor agonist drug shortage updates and resolution notices. FDA Drug Shortages database
- Centers for Medicare & Medicaid Services. Coverage of anti-obesity medications under Part D: policy background. https://www.cms.gov/
- Institute for Clinical and Economic Review (ICER). Assessments of GLP-1 therapies for obesity: pricing and value. https://icer.org/
We update this article as new data and regulatory decisions publish. Last reviewed: July 2026.